Legend Biotech (LEGN) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- $0.09
- EPS estimate
- $0.06
- EPS surprise
- +59.86%
- Revenue surprise
- +8.86%
- Revenue
- $387.5M
- Revenue estimate
- $356.0M
- Reported
- Aug 11, 2026
Legend Biotech reported Q2 2026 results on August 11, 2026. Earnings per share were $0.09, ahead of the $0.06 estimate by 59.86%. Revenue was $387.5 million, above the $356.0 million consensus. A year earlier, Q2 2025 was a loss of $0.34 per share, and revenue has since risen about 52% from $255.1 million.
The quarter was only the second profitable one in the table, after $0.07 per share in Q4 2024. Legend posted losses in the other 18 quarters, including $0.15 per share in Q1 2026. Annual losses were $1.17 per share in 2022, $1.48 in 2023, $0.48 in 2024 and $0.80 in 2025. Revenue grew much faster, from $111.0 million in 2022 to $285.1 million in 2023, $627.2 million in 2024 and $1.03 billion in 2025. Q2 2026 revenue was the highest in the table. Over the 20 quarters shown, Legend topped the EPS estimate 10 times, but only once in the last four quarters.
Legend reported Q3 between November 12 and November 20 in 2021, 2023, 2024 and 2025. That points to mid-November 2026 for the next report. It will show whether the company stays profitable after the latest quarter and whether revenue keeps rising.
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Aug 11, 2026 | $0.06 | $0.09 | +59.86% | $387.5M | SEC |
| Q1 2026 | May 12, 2026 | $0.01 | −$0.15 | −1319.51% | $305.1M | SEC |
| Q4 2025 | Mar 10, 2026 | $0.00 | −$0.08 | −16100.00% | $306.3M | SEC |
| Q3 2025 | Nov 12, 2025 | −$0.07 | −$0.11 | −51.31% | $272.3M | SEC |
| Q2 2025 | Aug 11, 2025 | −$0.11 | −$0.34 | −199.56% | $255.1M | SEC |
| Q1 2025 | May 13, 2025 | −$0.21 | −$0.27 | −28.33% | $195.1M | SEC |
| Q4 2024 | Mar 11, 2025 | −$0.25 | $0.07 | +128.29% | $186.5M | SEC |
| Q3 2024 | Nov 12, 2024 | −$0.33 | −$0.34 | −3.12% | $160.2M | SEC |
| Q2 2024 | Aug 9, 2024 | −$0.29 | −$0.05 | +82.60% | $186.5M | SEC |
| Q1 2024 | May 13, 2024 | −$0.19 | −$0.16 | +17.31% | $94.0M | SEC |
| Q4 2023 | Mar 11, 2024 | −$0.36 | −$0.40 | −12.49% | $79.5M | SEC |
| Q3 2023 | Nov 20, 2023 | −$0.31 | −$0.17 | +45.18% | $96.0M | SEC |
| Q2 2023 | Aug 15, 2023 | −$0.36 | −$0.57 | −57.94% | $73.3M | SEC |
| Q1 2023 | May 18, 2023 | −$0.42 | −$0.34 | +18.56% | $36.3M | SEC |
| Q4 2022 | Mar 30, 2023 | −$0.38 | −$0.32 | +16.47% | $27.5M | SEC |
| Q3 2022 | Invalid Date | −$0.37 | −$0.37 | +0.88% | $27.5M | — |
| Q2 2022 | Invalid Date | −$0.31 | −$0.35 | −12.83% | $15.2M | — |
| Q1 2022 | Jun 1, 2022 | −$0.36 | −$0.13 | +63.72% | $40.8M | — |
| Q4 2021 | Mar 18, 2022 | −$0.34 | −$0.30 | +12.23% | $39.0M | — |
| Q3 2021 | Nov 16, 2021 | −$0.42 | −$0.43 | −3.46% | $16.9M | — |
Quarterly revenue
Frequently asked questions
When did Legend Biotech (LEGN) last report earnings?
Legend Biotech last reported on Aug 11, 2026, covering fiscal Q2 2026.
Did LEGN beat earnings estimates?
Yes. Legend Biotech reported EPS of $0.09 for Q2 2026 against a $0.06 estimate — a 59.86% beat.
How much revenue did LEGN report last quarter?
Legend Biotech reported $387.5M in revenue for Q2 2026, against a consensus estimate of $356.0M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.